US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kyverna Therapeutics

3.47

+0.400013.03%

Post-market: 3.540.0700+2.02%19:17 EDT

Volume:852.40K

Turnover:2.87M

Market Cap:149.97M

PE:-1.03

High:3.61

Open:3.15

Low:3.10

Close:3.07

Loading ...

Overview Company News Filings

Analysts Offer Insights on NA Companies: Kyverna Therapeutics, Inc. (KYTX) and Boundless Bio Inc. (BOLD)

Kyverna Therapeutics Is Maintained at Overweight by Morgan Stanley

Kyverna Therapeutics Inc : Morgan Stanley Cuts Target Price to $20 From $40

THOMSON REUTERS

Kyverna Therapeutics price target lowered to $12 from $13 at UBS

Kyverna Therapeutics Advances CAR T-Cell Therapy Trials

Kyverna Therapeutics Inc Strong Balance Sheet Extends Cash Runway Into 2027 Through Key Clinical And Regulatory Catalysts

Kyverna Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

BRIEF-Kyverna Therapeutics Inc Files For Mixed Shelf Of Up To $250 Million - SEC Filing

Kyverna Therapeutics files $250M mixed securities shelf

Kyverna Therapeutics Inc Files for Mixed Shelf of up to $250 Mln - SEC Filing

THOMSON REUTERS

Kyverna Therapeutics Inc: Strong Balance Sheet Extends Cash Runway Into 2027 Through Key Clinical and Regulatory Catalysts

THOMSON REUTERS

Kyverna Therapeutics sees cash and securities sufficient into 2027

Kyverna Therapeutics FY24 EPS ($3.33) Up From ($89.61) YoY.

Calendar of U.S. Earnings Expected in the Week Ahead

Kyverna Therapeutics Inc expected to post a loss of 84 cents a share - Earnings Preview

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock

Kyverna Therapeutics Names Naji Gehchan as Chief Medical, Development Officer

MT Newswires Live

Kyverna Therapeutics Taps Naji Gehchan as Medical and Development Chief

Kyverna appoints Naji Gehchan as Chief Medical and Development Officer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/KYTX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KYTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYTX\",,,,,undefined,":{"symbol":"KYTX","market":"US","secType":"STK","nameCN":"Kyverna Therapeutics","latestPrice":3.47,"timestamp":1750968000000,"preClose":3.07,"halted":0,"volume":852401,"hourTrading":{"tag":"盘后","latestPrice":3.54,"preClose":3.47,"latestTime":"19:17 EDT","volume":2221,"amount":7775.8702512,"timestamp":1750979855622},"delay":0,"floatShares":22191720,"shares":43218873,"eps":-3.366184,"marketStatus":"Post-Mkt","change":0.4,"latestTime":"06-26 19:27:58 EDT","open":3.15,"high":3.605,"low":3.1,"amount":2870459.8560594,"amplitude":0.164495,"askPrice":3.58,"askSize":100,"bidPrice":3.42,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":-3.366184,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1750982400000},"marketStatusCode":4,"adr":0,"listingDate":1707368400000,"exchange":"NASDAQ","adjPreClose":3.07,"postHourTrading":{"tag":"盘后","latestPrice":3.54,"preClose":3.47,"latestTime":"19:17 EDT","volume":2221,"amount":7775.8702512,"timestamp":1750979855622},"volumeRatio":2.210566,"impliedVol":1.5676,"impliedVolPercentile":0.944},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYTX\",,,,,undefined,":{"symbol":"KYTX","floatShares":22191720,"roa":"-31.08%","roe":"-49.72%","lyrEps":-3.325379,"volumeRatio":2.210566,"shares":43218873,"dividePrice":0,"high":3.605,"amplitude":0.164495,"preClose":3.07,"low":3.1,"week52Low":1.78,"pbRate":"0.67","psRate":"531.81","week52High":11.4,"institutionHeld":0,"latestPrice":3.47,"committee":0.960784,"eps":-3.366184,"divideRate":0,"volume":852401,"delay":0,"ttmEps":-3.366184,"open":3.15,"prevYearClose":3.74,"prevWeekClose":3.07,"prevMonthClose":2.55,"prevQuarterClose":1.93,"fiveDayClose":2.91,"twentyDayClose":2.55,"sixtyDayClose":1.93},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KYTX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524419464","title":"Analysts Offer Insights on NA Companies: Kyverna Therapeutics, Inc. (KYTX) and Boundless Bio Inc. (BOLD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2524419464","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524419464?lang=en_us&edition=fundamental","pubTime":"2025-04-03 00:20","pubTimestamp":1743610809,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Kyverna Therapeutics, Inc. (KYTX – Research Report) and Boun...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-kyverna-therapeutics-inc-kytx-and-boundless-bio-inc-bold?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-kyverna-therapeutics-inc-kytx-and-boundless-bio-inc-bold?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NA","KYTX","BK4141","BOLD","BK4139"],"gpt_icon":0},{"id":"2524156221","title":"Kyverna Therapeutics Is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2524156221","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524156221?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:42","pubTimestamp":1743511320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KYTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 01, 2025 08:42 ET (12:42 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX"],"gpt_icon":0},{"id":"2524194288","title":"Kyverna Therapeutics Inc : Morgan Stanley Cuts Target Price to $20 From $40","url":"https://stock-news.laohu8.com/highlight/detail?id=2524194288","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524194288?lang=en_us&edition=fundamental","pubTime":"2025-04-01 19:10","pubTimestamp":1743505849,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nFWN3QF0Q9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYTX"],"gpt_icon":0},{"id":"2523618402","title":"Kyverna Therapeutics price target lowered to $12 from $13 at UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2523618402","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523618402?lang=en_us&edition=fundamental","pubTime":"2025-03-29 23:50","pubTimestamp":1743263405,"startTime":"0","endTime":"0","summary":"UBS lowered the firm’s price target on Kyverna Therapeutics (KYTX) to $12 from $13 and keeps a Buy rating on the shares. The company reported Q4 ea...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kyverna-therapeutics-price-target-lowered-to-12-from-13-at-ubs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kyverna-therapeutics-price-target-lowered-to-12-from-13-at-ubs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYTX"],"gpt_icon":0},{"id":"2523668751","title":"Kyverna Therapeutics Advances CAR T-Cell Therapy Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2523668751","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523668751?lang=en_us&edition=fundamental","pubTime":"2025-03-29 12:02","pubTimestamp":1743220925,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics, Inc. ( ($KYTX) ) has released its Q4 earnings. Here is a breakdown of the information Kyverna Therapeutics, Inc. presented to...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kyverna-therapeutics-advances-car-t-cell-therapy-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kyverna-therapeutics-advances-car-t-cell-therapy-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4230","BK4139","CAR","BK4022","KYTX"],"gpt_icon":0},{"id":"2522537306","title":"Kyverna Therapeutics Inc Strong Balance Sheet Extends Cash Runway Into 2027 Through Key Clinical And Regulatory Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2522537306","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522537306?lang=en_us&edition=fundamental","pubTime":"2025-03-28 05:12","pubTimestamp":1743109969,"startTime":"0","endTime":"0","summary":"March 27 (Reuters) - Kyverna Therapeutics Inc ::*KYVERNA THERAPEUTICS INC: STRONG BALANCE SHEET EXTENDS CASH RUNWAY INTO 2027 THROUGH KEY CLINICAL AND REGULATORY CATALYSTS  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 27-MAR-202520:02:02.617 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nRSD9LjlFC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2522532431","title":"Kyverna Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2522532431","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522532431?lang=en_us&edition=fundamental","pubTime":"2025-03-28 05:02","pubTimestamp":1743109344,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryKyverna Therapeutics Inc KYTX.OQ reported a quarterly adjusted loss of 88 cents per share for the quarter e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nL5N3QA26V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX"],"gpt_icon":0},{"id":"2522354532","title":"BRIEF-Kyverna Therapeutics Inc Files For Mixed Shelf Of Up To $250 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522354532","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522354532?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:53","pubTimestamp":1743108789,"startTime":"0","endTime":"0","summary":"BRIEF-Kyverna Therapeutics Inc Files For Mixed Shelf Of Up To $250 Million - SEC FilingMarch 27  - Kyverna Therapeutics Inc KYTX.O:KYVERNA THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $250 MILLION - SEC FILINGSource text: [ID:n0000950170-25-046162]Further company coverage: KYTX.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nFWN3QA1DB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2522532450","title":"Kyverna Therapeutics files $250M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2522532450","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522532450?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:50","pubTimestamp":1743108623,"startTime":"0","endTime":"0","summary":"16:49 EDT Kyverna Therapeutics (KYTX) files $250M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-movi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kyverna-therapeutics-files-250m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kyverna-therapeutics-files-250m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2522453405","title":"Kyverna Therapeutics Inc Files for Mixed Shelf of up to $250 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522453405","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522453405?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:49","pubTimestamp":1743108541,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nFWN3QA1DB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2522531641","title":"Kyverna Therapeutics Inc: Strong Balance Sheet Extends Cash Runway Into 2027 Through Key Clinical and Regulatory Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2522531641","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522531641?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:22","pubTimestamp":1743106923,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nFWN3QA1I1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYTX"],"gpt_icon":0},{"id":"2522531690","title":"Kyverna Therapeutics sees cash and securities sufficient into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2522531690","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522531690?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:10","pubTimestamp":1743106232,"startTime":"0","endTime":"0","summary":"Kyverna reported $286.0M in cash, cash equivalents, and available-for-sale marketable securities as of December 31, 2024. The company expects this ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kyverna-therapeutics-sees-cash-and-securities-sufficient-into-2027?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kyverna-therapeutics-sees-cash-and-securities-sufficient-into-2027?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KYTX"],"gpt_icon":0},{"id":"2522539112","title":"Kyverna Therapeutics FY24 EPS ($3.33) Up From ($89.61) YoY.","url":"https://stock-news.laohu8.com/highlight/detail?id=2522539112","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522539112?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:09","pubTimestamp":1743106190,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics FY24 EPS ($3.33) Up From ($89.61) YoY.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44523888/kyverna-therapeutics-fy24-eps-3-33-up-from-89-61-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX"],"gpt_icon":0},{"id":"2522329609","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2522329609","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522329609?lang=en_us&edition=fundamental","pubTime":"2025-03-27 18:00","pubTimestamp":1743069600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·INmune Bio Inc.                                 4Q      (.55)  4:05 PM. ·TD SYNNEX Corp                                   1Q      2.91   8:05 AM","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DARE","LULU","EDAP","PRGS","BCAB","ATAI","BW","NCNO","BHST","ADCT","FBIO","FEMY","SGML","SLRN","GOVX","FC","RLMD","SKYH","TSAT","WKSP","GWH","AFMD","WGO","ANGO","MDAI","NUTX","INR","FTCI","TLSI","CLSD","CRDL","PVLA","INMB","NNOX","PENG","SPWH","IKT","CALC","BLRX","PVH","KYTX","GEVO","RANI","SDST","WBA","REKR","CELC","LNZA","UNCY","BRZE"],"gpt_icon":0},{"id":"2521517822","title":"Kyverna Therapeutics Inc  expected to post a loss of 84 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2521517822","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521517822?lang=en_us&edition=fundamental","pubTime":"2025-03-22 04:13","pubTimestamp":1742587986,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics Inc  expected to post a loss of84cents a share - Earnings Preview Kyverna Therapeutics Inc KYTX.OQ KYTX.O is expected to show no change in quarterly revenue when it reports  resul","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nL8N3Q4214:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX"],"gpt_icon":0},{"id":"2516683666","title":"Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2516683666","media":"PR Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516683666?lang=en_us&edition=fundamental","pubTime":"2025-03-04 05:05","pubTimestamp":1741035900,"startTime":"0","endTime":"0","summary":"EMERYVILLE, Calif., March 3, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the Leerink Partners Global Biopharma Conference in Miami, FL on Monday, March 10, 2025, at 3:00 p.m. ET.A live webcast of the presentation may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. A replay of the webcast will be available on the website for 30 days following the conference.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/kyverna-therapeutics-present-leerink-partners-210500221.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kyverna-therapeutics-present-leerink-partners-210500221.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2510895453","title":"What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2510895453","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510895453?lang=en_us&edition=fundamental","pubTime":"2025-02-11 01:00","pubTimestamp":1739206811,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics, Inc.  could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 . This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.As such, the Zacks rating upgrade for Kyverna Therapeutics, Inc. is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.For Kyverna Therapeutics, Inc. rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.This company is expected to earn -$3.29 per share for the fi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/makes-kyverna-therapeutics-inc-kytx-170011008.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2505105738","title":"Kyverna Therapeutics Names Naji Gehchan as Chief Medical, Development Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2505105738","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505105738?lang=en_us&edition=fundamental","pubTime":"2025-01-22 06:17","pubTimestamp":1737497842,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics  said late Tuesday it appointed Naji Gehchan as chief medical and development officer.Gehchan most recently served as the head of clinical development for the imlunestrant breast cancer treatment at Eli Lilly .Shares of Kyverna Therapeutics were up 3% in after-hours trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SG9999018865.SGD","LLY","LU1069344957.HKD","SG9999014914.USD","LU1712237335.SGD","KYTX","LU2112291526.USD","LU0079474960.USD","LU2237443549.SGD","LU0823416689.USD","LU0385154629.USD","LU2491049909.HKD","LU2237443382.USD","LU1623119135.USD","LU1551013342.USD","LU1868836757.USD","LU2063271972.USD","LU1988902786.USD","LU0471298694.HKD","LU0672654240.SGD","LU2237443978.SGD","SG9999001176.USD","LU0114720955.EUR","IE00BJT1NW94.SGD","LU1804176565.USD","LU2211815571.USD","LU2491050154.USD","LU1720051017.SGD","SG9999014906.USD","BK4599","LU0109391861.USD","LU0106261372.USD","BK4581","LU0203201768.USD","LU0640476718.USD","LU1548497426.USD","LU1551013425.SGD","LU2468319806.SGD","LU1057294990.SGD","LU1267930730.SGD","LU0417517546.SGD","LU2106854487.HKD","SG9999015945.SGD","SG9999015952.SGD","LU0882574139.USD","BK4534","LU1093756168.USD","LU2265009873.SGD","LU1093756325.SGD","LU0203202063.USD"],"gpt_icon":0},{"id":"2505738174","title":"Kyverna Therapeutics Taps Naji Gehchan as Medical and Development Chief","url":"https://stock-news.laohu8.com/highlight/detail?id=2505738174","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505738174?lang=en_us&edition=fundamental","pubTime":"2025-01-22 06:17","pubTimestamp":1737497820,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics said it named Naji Gehchan as its chief medical and development officer.The clinical-stage biopharmaceutical company on Tuesday said that Gehchan comes from Eli Lilly, where he most recently served as the head of clinical development for breast cancer treatment imlunestrant.As part of this appointment, Kyverna's current president of research and development, Dominic Borie, will move to a new role as strategic advisor to Chief Executive Officer Warner Biddle and the board.Borie in the past acted as the founding CEO at Kyverna.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"gpt_icon":0},{"id":"2505782285","title":"Kyverna appoints Naji Gehchan as Chief Medical and Development Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2505782285","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505782285?lang=en_us&edition=fundamental","pubTime":"2025-01-22 05:10","pubTimestamp":1737493823,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics (KYTX) announced the appointment of Naji Gehchan, to Chief Medical and Development Officer, where he will lead the Company’s r...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kyverna-appoints-naji-gehchan-as-chief-medical-and-development-officer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kyverna-appoints-naji-gehchan-as-chief-medical-and-development-officer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYTX","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":54,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KYTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-13","symbol":"KYTX","fiscalQuarterEnding":"2025/03","expectedEps":-1.21,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"post","actualEps":-1.03},{"market":"US","date":"2025-03-27","symbol":"KYTX","fiscalQuarterEnding":"2024/12","expectedEps":-0.87,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"post","actualEps":-0.88},{"market":"US","date":"2024-11-13","symbol":"KYTX","fiscalQuarterEnding":"2024/09","expectedEps":-0.77,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-0.8}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KYTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KYTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.8333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8333,"analysts":6,"updateTime":1748404800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KYTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KYTX","date":"2025-06-25","current":-0.948076,"percent":0.828488,"low":-26.836094,"twenty":-8.766622,"median":-2.97247,"eighty":-0.990191,"high":-0.615209,"avg":-5.913816,"sd":7.310849,"marketCap":137868204},"quantilePoints":[{"date":"2024-02-09","current":-25.410847,"twenty":-24.055602,"median":-22.022734,"eighty":-19.989866,"marketCap":1224675750},{"date":"2024-02-16","current":-26.541682,"twenty":-26.641604,"median":-26.505996,"eighty":-25.427787,"marketCap":1279176368},{"date":"2024-02-23","current":-24.230994,"twenty":-26.541682,"median":-25.495549,"eighty":-24.578936,"marketCap":1167812779},{"date":"2024-03-01","current":-24.239916,"twenty":-26.505996,"median":-25.105309,"eighty":-24.54325,"marketCap":1168242754},{"date":"2024-03-08","current":-25.676289,"twenty":-26.318643,"median":-25.069622,"eighty":-24.578936,"marketCap":1237468769},{"date":"2024-03-15","current":-26.354329,"twenty":-26.354329,"median":-25.311608,"eighty":-24.712759,"marketCap":1270146888},{"date":"2024-03-22","current":-23.999034,"twenty":-26.354329,"median":-25.16776,"eighty":-24.239916,"marketCap":1156633422},{"date":"2024-03-28","current":-17.2201,"twenty":-26.32578,"median":-25.042858,"eighty":-23.820602,"marketCap":1039508532},{"date":"2024-04-05","current":-15.927342,"twenty":-26.311505,"median":-24.815357,"eighty":-20.313915,"marketCap":961469941},{"date":"2024-04-12","current":-17.062969,"twenty":-25.959995,"median":-24.578936,"eighty":-17.608641,"marketCap":1030023179},{"date":"2024-04-19","current":-13.577524,"twenty":-25.715544,"median":-24.235455,"eighty":-16.573007,"marketCap":819620788},{"date":"2024-04-26","current":-11.384836,"twenty":-25.597779,"median":-23.86521,"eighty":-16.071617,"marketCap":687256989},{"date":"2024-05-03","current":-10.734886,"twenty":-25.51207,"median":-23.093494,"eighty":-15.443094,"marketCap":648022117},{"date":"2024-05-10","current":-10.427767,"twenty":-25.427787,"median":-18.634621,"eighty":-13.461819,"marketCap":629482562},{"date":"2024-05-17","current":-8.660987,"twenty":-25.252064,"median":-17.663681,"eighty":-11.317698,"marketCap":657507471},{"date":"2024-05-24","current":-7.059414,"twenty":-25.176682,"median":-17.2201,"eighty":-10.732029,"marketCap":535922482},{"date":"2024-05-31","current":-7.116207,"twenty":-25.108877,"median":-16.627288,"eighty":-10.256351,"marketCap":540234007},{"date":"2024-06-07","current":-7.456968,"twenty":-25.053564,"median":-16.309455,"eighty":-9.030538,"marketCap":566103153},{"date":"2024-06-14","current":-5.412407,"twenty":-25.026799,"median":-16.020192,"eighty":-8.479248,"marketCap":410888275},{"date":"2024-06-21","current":-4.390126,"twenty":-24.958995,"median":-15.870204,"eighty":-7.953341,"marketCap":333280836},{"date":"2024-06-28","current":-4.259502,"twenty":-24.826956,"median":-14.259614,"eighty":-7.613717,"marketCap":323364330},{"date":"2024-07-05","current":-3.978375,"twenty":-24.748445,"median":-13.641804,"eighty":-7.429707,"marketCap":302022284},{"date":"2024-07-12","current":-5.56007,"twenty":-24.685994,"median":-12.649024,"eighty":-7.150283,"marketCap":422098238},{"date":"2024-07-19","current":-5.685015,"twenty":-24.571799,"median":-11.216991,"eighty":-6.028046,"marketCap":431583592},{"date":"2024-07-26","current":-5.588466,"twenty":-24.482583,"median":-10.813451,"eighty":-5.596417,"marketCap":424254000},{"date":"2024-08-02","current":-4.117518,"twenty":-24.238132,"median":-10.584898,"eighty":-5.421494,"marketCap":312585519},{"date":"2024-08-09","current":-3.725644,"twenty":-24.184602,"median":-9.999228,"eighty":-5.056881,"marketCap":282836000},{"date":"2024-08-16","current":-3.830678,"twenty":-23.972269,"median":-9.395703,"eighty":-4.700218,"marketCap":290809782},{"date":"2024-08-23","current":-4.597951,"twenty":-23.820602,"median":-8.80297,"eighty":-4.562778,"marketCap":349058032},{"date":"2024-08-30","current":-4.56385,"twenty":-23.561877,"median":-8.433813,"eighty":-4.558634,"marketCap":346469221},{"date":"2024-09-06","current":-4.171688,"twenty":-23.2407,"median":-8.189602,"eighty":-4.480996,"marketCap":316697893},{"date":"2024-09-13","current":-4.092119,"twenty":-22.946288,"median":-7.78069,"eighty":-4.395806,"marketCap":310657334},{"date":"2024-09-20","current":-3.631756,"twenty":-20.733738,"median":-7.624508,"eighty":-4.308092,"marketCap":275708384},{"date":"2024-09-27","current":-2.97247,"twenty":-18.634621,"median":-7.456968,"eighty":-4.211473,"marketCap":225658035},{"date":"2024-10-04","current":-2.63146,"twenty":-17.741488,"median":-7.394495,"eighty":-4.171688,"marketCap":199769924},{"date":"2024-10-11","current":-2.983837,"twenty":-17.707293,"median":-7.116207,"eighty":-4.052335,"marketCap":226520973},{"date":"2024-10-18","current":-3.205494,"twenty":-17.620069,"median":-6.641982,"eighty":-3.978375,"marketCap":243348245},{"date":"2024-10-25","current":-2.909952,"twenty":-17.56293,"median":-5.951944,"eighty":-3.964176,"marketCap":220911882},{"date":"2024-11-01","current":-2.779231,"twenty":-17.2201,"median":-5.608344,"eighty":-3.873307,"marketCap":210988106},{"date":"2024-11-08","current":-3.006571,"twenty":-17.062969,"median":-5.514635,"eighty":-3.751109,"marketCap":228246847},{"date":"2024-11-15","current":-1.697135,"twenty":-16.627288,"median":-5.392529,"eighty":-3.322005,"marketCap":187796512},{"date":"2024-11-22","current":-1.712741,"twenty":-16.355881,"median":-5.065967,"eighty":-3.177076,"marketCap":189523376},{"date":"2024-11-29","current":-2.251143,"twenty":-16.350167,"median":-4.969419,"eighty":-3.054313,"marketCap":249100201},{"date":"2024-12-06","current":-1.775165,"twenty":-16.285886,"median":-4.789428,"eighty":-3.003161,"marketCap":196430834},{"date":"2024-12-13","current":-1.724446,"twenty":-16.121613,"median":-4.674093,"eighty":-2.977017,"marketCap":190818525},{"date":"2024-12-20","current":-1.560584,"twenty":-16.033048,"median":-4.573541,"eighty":-2.950873,"marketCap":172686448},{"date":"2024-12-27","current":-1.556683,"twenty":-15.964482,"median":-4.562178,"eighty":-2.903132,"marketCap":172254731},{"date":"2025-01-03","current":-1.599599,"twenty":-15.904487,"median":-4.538274,"eighty":-2.797418,"marketCap":177003609},{"date":"2025-01-10","current":-1.346004,"twenty":-15.82735,"median":-4.480996,"eighty":-2.693979,"marketCap":148942061},{"date":"2025-01-17","current":-1.299186,"twenty":-15.443094,"median":-4.435561,"eighty":-2.615547,"marketCap":143761467},{"date":"2025-01-24","current":-1.404526,"twenty":-14.591731,"median":-4.395806,"eighty":-2.532048,"marketCap":155417803},{"date":"2025-01-31","current":-1.264073,"twenty":-13.927497,"median":-4.353211,"eighty":-2.095084,"marketCap":139876022},{"date":"2025-02-07","current":-1.170438,"twenty":-13.706085,"median":-4.259502,"eighty":-1.931223,"marketCap":129514836},{"date":"2025-02-14","current":-1.182143,"twenty":-13.577524,"median":-4.21845,"eighty":-1.814179,"marketCap":130809984},{"date":"2025-02-21","current":-1.084606,"twenty":-13.114702,"median":-4.187318,"eighty":-1.73693,"marketCap":120017081},{"date":"2025-02-28","current":-1.108015,"twenty":-12.719019,"median":-4.171688,"eighty":-1.688552,"marketCap":122607378},{"date":"2025-03-07","current":-1.01438,"twenty":-12.020501,"median":-4.104819,"eighty":-1.598038,"marketCap":112246191},{"date":"2025-03-14","current":-0.975365,"twenty":-11.480543,"median":-3.998252,"eighty":-1.555903,"marketCap":107929030},{"date":"2025-03-21","current":-0.928548,"twenty":-11.116285,"median":-3.978412,"eighty":-1.525471,"marketCap":102748436},{"date":"2025-03-28","current":-0.678003,"twenty":-10.923443,"median":-3.972766,"eighty":-1.481775,"marketCap":86429836},{"date":"2025-04-04","current":-0.671223,"twenty":-10.829164,"median":-3.959945,"eighty":-1.403746,"marketCap":85565537},{"date":"2025-04-11","current":-0.698343,"twenty":-10.750599,"median":-3.915931,"eighty":-1.33508,"marketCap":89022731},{"date":"2025-04-17","current":-0.630601,"twenty":-10.726315,"median":-3.836362,"eighty":-1.299186,"marketCap":80387103},{"date":"2025-04-25","current":-0.711969,"twenty":-10.557757,"median":-3.76816,"eighty":-1.283581,"marketCap":90759633},{"date":"2025-05-02","current":-0.772995,"twenty":-10.436338,"median":-3.711325,"eighty":-1.243785,"marketCap":98539030},{"date":"2025-05-09","current":-0.715359,"twenty":-10.170644,"median":-3.266591,"eighty":-1.184484,"marketCap":91191822},{"date":"2025-05-16","current":-0.68951,"twenty":-9.982087,"median":-3.188443,"eighty":-1.152492,"marketCap":100267785},{"date":"2025-05-23","current":-0.73409,"twenty":-9.837812,"median":-3.142975,"eighty":-1.119719,"marketCap":106750616},{"date":"2025-05-30","current":-0.781642,"twenty":-9.466412,"median":-3.049198,"eighty":-1.09553,"marketCap":113665635},{"date":"2025-06-06","current":-0.873775,"twenty":-9.030538,"median":-3.023622,"eighty":-1.030766,"marketCap":127063486},{"date":"2025-06-13","current":-1.02832,"twenty":-8.929052,"median":-2.986679,"eighty":-1.018767,"marketCap":149537300},{"date":"2025-06-20","current":-0.864859,"twenty":-8.793883,"median":-2.980995,"eighty":-1.008108,"marketCap":125766920},{"date":"2025-06-25","current":-0.948076,"twenty":-8.766622,"median":-2.97247,"eighty":-0.990191,"marketCap":137868204}],"updateTime":1750975214752}}}